BeyondSpring Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
BeyondSpring Inc. (BYSI) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $386.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-14
- BeyondSpring Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $194.00K, a 4.86% increase year-over-year.
- BeyondSpring Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $192.00K, a 4.35% increase year-over-year.
- BeyondSpring Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $190.00K, a 6.74% increase year-over-year.
- BeyondSpring Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $188.00K, a 6.21% increase year-over-year.
- BeyondSpring Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $747.00K, a 6.41% increase from fiscal 2024.
- BeyondSpring Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $702.00K, a 35.36% decline from fiscal 2023.
- BeyondSpring Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $1.09M.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $194.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $386.00K 10-Q · filed 2026-08-14 | $576.00K derived: sum of 3 quarters · filed 2026-08-14 | $764.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $192.00K 10-Q · filed 2026-05-13 | $382.00K derived: sum of 2 quarters · filed 2026-05-13 | $570.00K derived: sum of 3 quarters · filed 2026-05-13 | $755.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $190.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $378.00K derived: sum of 2 quarters · filed 2026-03-25 | $563.00K derived: sum of 3 quarters · filed 2026-08-14 | $747.00K 10-K · filed 2026-03-25 |
| 2025-09-30 | $188.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $373.00K derived: sum of 2 quarters · filed 2026-08-14 | $557.00K 10-Q · filed 2025-11-12 | $735.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $185.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $369.00K 10-Q · filed 2026-08-14 | $547.00K derived: sum of 3 quarters · filed 2026-08-14 | $724.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $184.00K 10-Q · filed 2026-05-13 | $362.00K derived: sum of 2 quarters · filed 2026-05-13 | $539.00K derived: sum of 3 quarters · filed 2026-05-13 | $713.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $178.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $355.00K derived: sum of 2 quarters · filed 2026-03-25 | $529.00K derived: sum of 3 quarters · filed 2026-03-25 | $702.00K 10-K · filed 2026-03-25 |
| 2024-09-30 | $177.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $351.00K derived: sum of 2 quarters · filed 2025-11-12 | $524.00K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $174.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $347.00K 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $173.00K 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $1.09M 10-K · filed 2025-03-27 | |||
| 2022-12-31 | $912.00K 20-F · filed 2023-04-18 | |||
| 2021-12-31 | $180.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-04-18 | $324.00K derived: sum of 2 quarters · filed 2023-04-18 | $447.00K derived: sum of 3 quarters · filed 2023-04-18 | $546.00K 20-F · filed 2023-04-18 |
| 2021-09-30 | $144.00K derived: 6-K 9 month − 6-K 6 month · filed 2021-12-30 | $267.00K derived: sum of 2 quarters · filed 2021-12-30 | $366.00K 6-K · filed 2021-12-30 | $568.00K derived: sum of 4 quarters · filed 2023-04-18 |
| 2021-06-30 | $123.00K derived: 6-K 6 month − 6-K 3 month · filed 2021-09-10 | $222.00K 6-K · filed 2021-09-10 | $424.00K derived: sum of 3 quarters · filed 2023-04-18 | $585.00K derived: sum of 4 quarters · filed 2023-04-18 |
| 2021-03-31 | $99.00K 6-K · filed 2021-06-16 | $301.00K derived: sum of 2 quarters · filed 2023-04-18 | $462.00K derived: sum of 3 quarters · filed 2023-04-18 | $601.00K derived: sum of 4 quarters · filed 2023-04-18 |
| 2020-12-31 | $202.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-04-18 | $363.00K derived: sum of 2 quarters · filed 2023-04-18 | $502.00K derived: sum of 3 quarters · filed 2023-04-18 | $659.00K 20-F · filed 2023-04-18 |
| 2020-09-30 | $161.00K derived: 6-K 9 month − 6-K 6 month · filed 2021-12-30 | $300.00K derived: sum of 2 quarters · filed 2021-12-30 | $457.00K 6-K · filed 2021-12-30 | $728.00K derived: sum of 4 quarters · filed 2022-04-14 |
| 2020-06-30 | $139.00K derived: 6-K 6 month − 6-K 3 month · filed 2021-09-10 | $296.00K 6-K · filed 2021-09-10 | $567.00K derived: sum of 3 quarters · filed 2022-04-14 | $686.00K derived: sum of 4 quarters · filed 2022-04-14 |
| 2020-03-31 | $157.00K 6-K · filed 2021-06-16 | $428.00K derived: sum of 2 quarters · filed 2022-04-14 | $547.00K derived: sum of 3 quarters · filed 2022-04-14 | |
| 2019-12-31 | $271.00K derived: 20-F 12 month − 6-K 9 month · filed 2022-04-14 | $390.00K derived: sum of 2 quarters · filed 2022-04-14 | $650.00K 20-F · filed 2022-04-14 | |
| 2019-09-30 | $119.00K derived: 6-K 9 month − 6-K 6 month · filed 2020-11-17 | $379.00K 6-K · filed 2020-11-17 | ||
| 2019-06-30 | $260.00K 6-K · filed 2020-09-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |